This article is more than 5 years old. Information may no longer be current.
Edwards invests in structural heart technologies
Click Here to Manage Email Alerts
Edwards Lifesciences announced that it has conducted transactions involving two companies developing structural heart technologies.
The company stated in a press release that it has committed $35 million to acquire exclusive rights to buy Corvia Medical, which developed the first transcatheter device to treat HF with preserved or reduced ejection fraction (InterAtrial Shunt Device).
The device, which is designed to decompress the left atrium to reduce symptoms and slow progression of HF, received a CE mark and is the subject of an ongoing pivotal trial that will be the basis of an application for FDA approval, according to the release.
Edwards also stated in the release that it has acquired certain assets of Mitralign, which developed an investigational transcatheter annuloplasty system designed to treat functional mitral and tricuspid regurgitation. The assets include intellectual property rights and associated clinical and regulatory experience. Terms of the deal were not disclosed.